Get started
Author

Judit Mészáros Joergensen

Observed names: J. Joergensen, Joergensen, J., Judit Joergensen, Judit M. Joergensen, Judit M. Jørgensen, Judit Meszaros Joergensen
Observed institution: Aarhus University Hospital
ORCID: 0000-0001-9784-2703
Observed ORCID: 0000-0001-9784-2703
OpenAlex ID: A5026722843
Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results
2023 · Lorenzo Falchi, Fabrice Jardin, et al. · Blood · 20
Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study
2023 · Martin Hutchings, Abraham Avigdor, et al. · Blood · 19
Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study
2024 · Martin Hutchings, Anna Sureda Balari, et al. · Blood · 15
Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
2023 · Julio C. Chavez, Loretta J. Nastoupil, et al. · Blood · 14
Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2
2023 · Joshua Brody, Judit Mészáros Joergensen, et al. · Blood · 10
Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.
2019 · Grzegorz S. Nowakowski, Wolfgang Willenbacher, et al. · Journal of Clinical Oncology · 10
Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas
2014 · Francesco d'Amore, Judit Joergensen, et al. · Blood · 7
Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2.
2024 · Joshua D. Brody, Judit Meszaros Joergensen, et al. · Journal of Clinical Oncology · 5
Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study
2024 · Julio C. Chavez, Guilherme Fleury Perini, et al. · Blood · 4
152 | GLOFITAMAB+R‐CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED LARGE B‐CELL LYMPHOMA DEFINED AS HIGH RISK BY CIRCULATING TUMOR DNA (ctDNA) DYNAMICS: PRIMARY RESULTS
2025 · M. Nijland, F. Jardin, et al. · Hematological Oncology · 2
PDF
Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial)
2016 · Sirpa Leppa, Judit Joergensen, et al. · Blood · 2
First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma
2026 · Umberto Vitolo, Lorenzo Falchi, et al. · HemaSphere · 1
Outcome of T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in Denmark 2008-2022
2024 · Peter Brændstrup, Thomas Bech Mortensen, et al. · Blood · 1
PDF
Dose-Dense Chemoimmunotherapy and Early CNS Prophylaxis for High-Risk DLBCL.:Interim Results from a Nordic Phase II Study
2015 · Leppa, S, Joergensen, J., et al. · University of Southern Denmark Research Portal (University of Southern Denmark) · 1
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD ± rituximab (R) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Long-term follow-up (f/u) of the phase (Ph) 1/2 CC-99282-NHL-001 study.
2026 · Javier Munoz, Julio C. Chavez, et al. · Journal of Clinical Oncology
Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
2024 · Nancy L. Bartlett, Jeong-A Kim, et al. · Blood
PDF
Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas
2024 · Miro Nylén, Leo Meriranta, et al. · Blood
PDF
Temporal Trends in Relative Survival of Diffuse Large B-Cell Lymphoma in Sweden and Denmark in the Era of Targeted and Cellular Therapies: A Population-Based Binational Study
2024 · Sara Harrysson, Sandra Eloranta, et al. · Blood
Differences in Overall Survival for Non-Western Immigrant Patients Compared to Danish-Born Patients with Diffuse Large B-Cell Lymphoma
2023 · Mikkel Runason Simonsen, Lasse Hjort Jakobsen, et al. · Blood
PDF
Abstract 980: Clinical impact of T-cell exhaustion in patients with diffuse large B-cell lymphoma
2019 · Suvi-Katri Leivonen, Matias Autio, et al. · Tumor Biology
Abstract 980: Clinical impact of T-cell exhaustion in patients with diffuse large B-cell lymphoma
2019 · Suvi-Katri Leivonen, Matias Autio, et al. · Cancer Research
Works count: 21
Citation count: 111
H-index: 7
I10-index: 6
Year
Topic
Type